Jinhyuk Fred Chung, President and CSO, Xylonix
Cancer is one of the world’s largest health problems. Even the World Health Organization (WHO) reports that cancer is the second leading cause of death globally, accounting for about 9.6 million deaths in 2018. Though there are a plethora of techniques to cure this deadly disease, cancer immunotherapy stands out as a promising treatment methodology. It involves stimulating the human body’s natural immune system to fight cancer by binding immunotherapy antibodies so that the mutant cells can be easily identified and killed.
Currently, many pharma-led cancer immunotherapy organizations advance to make durable and potentially curative cancer treatments. However, they demonstrate cure potentials only across narrow cancer types, and the problems of unpredictable treatment responses and low patient responses rate remain unaltered. Besides, these treatments have three major setbacks as limited applicability, low reliability, and high cost because of the current market trend of ‘personalized combination treatments.’ It drives up cancer care costs between the increased number of new drugs and decreasing beneficiary pool. In this backdrop, enormous recourses have been invested by the pharma and non-profit organizations with only limited success so far, expecting a co-treatment with an effective agent that may help address these problems.
As a solution to these challenges, Xylonix, an innovative cancer immunotherapy biotechnology company, stands head over the shoulder with its competitors through its best-in-class agent, 010DS-Zn. This flagship innovation of the company is a novel triple-action drug that kills cancer and simultaneously initiates two types of anti-tumor immunity attacks by T-cell and macrophages. With this Onco-Parthanatos technology, Xylonix kills and turns cancer into its own inflammatory antigens and initiates effective anti-cancer immune responses. Jinhyuk Fred Chung, President and CSO of Xylonix, remarks on the agent as, “Using its versatility and dual-immune initiation action, 010DS-Zn turns existing immunotherapies into carpet bombs for reliably catching most cancers. Our data suggest that it can be used against a wide range of cancer types like the chemotherapies.” As 010DS-Zn is aimed to enable ‘generic combination immunotherapy,’ it also meets the cost barrier in the area of immunotherapy.
Using its versatility and dual-immune initiation action, 010DS-Zn turns existing immunotherapies into carpet bombs for reliably catching most cancers
Xylonix further reinstates its uniqueness in the marketplace, as 010DS-Zn is the only single-compound agent that simultaneously exerts the effects of an anti-tumor cytotoxic agent, T-cell response initiator, and macrophage response initiator. It has the distinctive potential to enable two or three combination cancer treatment regimens that comprehensively lock all known immune escape mechanisms to dramatically improve treatment outcomes. Whereas, if similar benefits were to be reproduced by combining single-action cancer drugs, it would require four to five drug combinations entailing prohibitively permuted development risks.
In addition to these technical factors, Xylonix understands that translational readiness is an important consideration factor for pharma and provides 100 percent of its development works from its manufacturing development to IND enabling studies consigned to industry-leading contract service organizations. Through this collaboration, the company ensures that its translational development data is objective and meets the pharma standards.
Studying the current and future courses of the COVID-19 closely, Xylonix, besides hoping the vaccine works, also contemplates on its counter-possibilities. It foresees the possible benefits of 010DS-Zn against the severe immune reactions of COVID-19, and due to the product’s immune-modulatory action, the company considers it to be potential applicability in the treatment of its severe cases.
In order to maximally leverage 010DS-Zn’s value toward the future dialects with pharma, Xylonix is investing heavily on the formulation optimization and screening programs in 2021 to demonstrate that certain combination therapies involving the drug can reliably achieve a complete response in wide cancer types. The company is also anticipating the following years to be intense, as it plans to enter 010DS-Zn into the first-in-human study in 2022. Xylonix also aims to comprehensively complete its combination screening study against arrays of solid and blood cancer types in 2022. The company believes that the progressive accumulation of evidence that the technology works as intended will help it find the key pharma collaboration towards its clinical developments.